LON:INS Instem (INS) Share Price, News & Analysis GBX 830 0.00 (0.00%) (As of 11/20/2023) Add Compare Share Share Stock Analysis Stock AnalysisHeadlines About Instem Stock (LON:INS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Instem alerts:Sign Up Key Stats Today's Range 830▼ 83050-Day Range 830▼ 83052-Week Range 580▼ 835.56Volume3,800 shsAverage Volume85,542 shsMarket Capitalization£199.62 millionP/E Ratio5,928.57Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewInstem plc, together with its subsidiaries, provides information technology solutions and services to the life sciences healthcare market worldwide. The company offers solutions for data collection, management, and analysis to meet the needs of life science and healthcare organizations for data-driven decision making. Its solutions include ALPHADAS, an eSource system for early phase clinical trials; BioRails for discovery data management; Comet Assay IV, a live video imaging system for reproducible comet slide scoring; and Cyto Study Manager, a data acquisition and reporting solution. The company also offers computational toxicology products and services; Blur Clinical Annonymization; Logbook ELN, a repository for information; Morphit for discovery data visualization; NOTOCORD-hem software platforms to acquire, display, and analyze physiological signals; and Provantis, a windows-based system for non-clinical evaluation studies. In addition, it provides Samarind RMS to manage medical product information; submit platform that offers tools and services for the creation and management of SEND datasets and associated documents for contract research organizations and sponsors; SENDView, an application that simplifies the review of SEND datasets; KnowledgeScan Target Safety Assessment services; SENDTrial, a web based solution that can be accessed through a subscription; and Predict delivers computational models. Further, the company provides Sorcerer Colony Counter; sales and administrative support; training, validation, consultancy, cloud, and safety assessment and regulatory information management software services; software solutions to extract intelligence from research and development related healthcare data; and holds intellectual property rights and investment. It also develops, manufactures, and supplies software and hardware products for in vitro study data collection and management. Instem plc was founded in 1969 and is headquartered in Stone, the United Kingdom.Read More… 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Receive INS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Instem and its competitors with MarketBeat's FREE daily newsletter. Email Address INS Stock News HeadlinesBiosimulation Market to Hit USD 9.18 Billion by 2029 with 16.7% CAGR | MarketsandMarkets™October 30 at 12:29 PM | finance.yahoo.comNew England Biolabs® Announces 2024 Passion in Science Awards® RecipientsSeptember 5, 2024 | tmcnet.comSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.November 2, 2024 | Chaikin Analytics (Ad)After uproar over hike in Budget, govt reverts to 10% customs duty on lab chemicals, with 1 conditionAugust 1, 2024 | msn.comSTEM program initially for New Town Native American students allows students from the rest of NDJuly 19, 2024 | msn.comThe Best Gravel Bike Shoes of 2024April 19, 2024 | msn.comThe Wrap: Maternal healthcareFebruary 13, 2024 | msn.comINSTEM expands to include all North Dakota Native studentsFebruary 13, 2024 | msn.comSee More Headlines INS Stock Analysis - Frequently Asked Questions How have INS shares performed this year? Instem's stock was trading at GBX 830 at the start of the year. Since then, INS shares have increased by 0.0% and is now trading at GBX 830. View the best growth stocks for 2024 here. How do I buy shares of Instem? Shares of INS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Instem own? Based on aggregate information from My MarketBeat watchlists, some other companies that Instem investors own include B&M European Value Retail (BME), Coats Group (COA), 4D pharma (DDDD), genedrive (GDR), Greencore Group (GNC), IQE (IQE) and Omega Diagnostics Group (ODX). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolLON:INS CUSIPN/A CIKN/A Webwww.instem.com Phone+44-1785-825600FaxN/AEmployees500Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX 0.14 Trailing P/E Ratio5,928.57 Forward P/E Ratio17.83 P/E Growth1.89Net Income£3.34 million Net Margins5.50% Pretax MarginN/A Return on Equity6.35% Return on Assets4.62% Debt Debt-to-Equity Ratio3.47 Current Ratio0.95 Quick Ratio0.84 Sales & Book Value Annual Sales£61.63 million Price / Sales3.24 Cash FlowGBX 54.41 per share Price / Cash Flow15.25 Book ValueGBX 239 per share Price / Book3.47Miscellaneous Outstanding Shares24,050,000Free FloatN/AMarket Cap£199.62 million OptionableNot Optionable Beta0.42 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (LON:INS) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Instem plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Instem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.